

CRIM2 Antibody

Catalog # ASC11522

Specification

CRIM2 Antibody - Product Information

Application Primary Accession Other Accession Reactivity Host Clonality

Clonality Isotype

Application Notes

WB

Q6ZWJ8

NP_001129386, 209571519

Human, Mouse, Rat

Rabbit Polyclonal

IgG

CRIM2 antibody can be used for detection of CRIM2 by Western blot at 1 - 2 μg/mL.

CRIM2 Antibody - Additional Information

Gene ID 375616

Target/Specificity

KCP; At least two isoforms of CRIM2 are known to exist; this antibody will only detect the larger isoform. CRIM2 antibody is predicted to not cross-react with CRIM1.

Reconstitution & Storage

CRIM2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Precautions

CRIM2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

CRIM2 Antibody - Protein Information

Name KCP (<u>HGNC:17585</u>)

Synonyms CRIM2, KCP1

Function

Enhances bone morphogenetic protein (BMP) signaling in a paracrine manner. In contrast, it inhibits both the activin-A and TGFB1-mediated signaling pathways (By similarity).

Cellular Location

Secreted.


CRIM2 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.



- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

CRIM2 Antibody - Images



Western blot analysis of CRIM2 in Jurkat cell lysate with CRIM2 antibody at (A) 1 and (B) 2 µg/mL.

CRIM2 Antibody - Background

CRIM2 Antibody: CRIM2, also known as Kielin/chordin-like protein (KCP), is a novel enhancer of BMP signaling. It binds to BMP7, a morphogen that is important for kidney development and part of the kidney's physiological response to repair of acute kidney injury, enhancing its binding to its receptor. Because of this, CRIM2 has been suggested as a potential antifibrotic therapy in acute and chronic kidney injury. CRIM2 can also interact directly with either activin or TGF- β 1, suppressing activin- and TGF- β 1-dependent transcription.

CRIM2 Antibody - References

Lin J, Patel SR, Cheng X, et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat. Med. 2005; 11:387-93

Zeisberg M and Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr. Nephrol. 2008; 23:1395-8.

Lin J, Patel SR, Wang M, et al. The cysteine-rich domain protein KCP is a suppressor of transforming growth factor β/Activin signaling in renal epithelia. Mol. Cell. Biol. 2006; 26:4577-85.